Sova Pharmaceuticals Inc. is a privately-held biopharmaceutical company founded in 2010. The company is engaged in the discovery and development of innovative therapeutics for the treatment of both inflammatory and neuropathic pain. These conditions represent large areas of unmet medical need as current therapies often provide unsatisfactory pain relief and few new molecular targets are being pursued. Our novel compounds offer the opportunity to benefit patients by treating inflammatory and neuropathic pain conditions at their source. There is mounting evidence that increased concentrations of H2S are contributory to certain disease states characterized by inflammatory-induced pain. Sova believes that modulation of cystathionine-γ-lyase (CSE), an enzymatic target involved in the production of the gasotransmitter H2S, is an opportunity to produce novel therapies to treat such disorders.